Link: http://www.independent.co.uk/news/sc...-a7060181.html
Published today in Nature: http://www.nature.com/nature/journal...ture18300.html
Full paper: http://sci-hub.cc/10.1038/nature18300
Patient tests:Scientists have taken a “very positive step” towards creating a universal vaccine against cancer that makes the body’s immune system attack tumours as if they were a virus, experts have said.
Writing in Nature, an international team of researchers described how they had taken pieces of cancer’s genetic RNA code, put them into tiny nanoparticles of fat and then injected the mixture into the bloodstreams of three patients in the advanced stages of the disease.
The patients' immune systems responded by producing "killer" T-cells designed to attack cancer.
The vaccine was also found to be effective in fighting “aggressively growing” tumours in mice, according to researchers, who were led by Professor Ugur Sahin from Johannes Gutenberg University in Germany.
“[Such] vaccines are fast and inexpensive to produce, and virtually any tumour antigen [a protein attacked by the immune system] can be encoded by RNA," they wrote
“Thus, the nanoparticulate RNA immunotherapy approach introduced here may be regarded as a universally applicable novel vaccine class for cancer immunotherapy.”
More technical detail:The paper said the three patients were given low doses of the vaccine and the aim of the trial was not to test how well the vaccine worked. While the patients' immune systems seemed to react, there was no evidence that their cancers went away as a result.
In one patient, a suspected tumour on a lymph node got smaller after they were given the vaccine. Another patient, whose tumours had been surgically removed, was cancer-free seven months after vaccination.
The third patient had eight tumours that had spread from the initial skin cancer into their lungs. These tumours remained “clinically stable” after they were given the vaccine, the paper said.
The vaccine, which used a number of different pieces of RNA, activated dendritic cells that select targets for the body's immune system to attack. This was followed by a strong response from the "killer" T-cells that normally deal with infections.
The team focussed on a class of immune cells call dendritic cells which are constantly on the look-out for foreign invaders in the body. Once a dendritic cell spots a rogue cell like cancer, it captures molecules from the surface and presents it to killer T-cells to instruct it to begin fighting the disease.
However cancer cells look very similar to normal cells and so the immune system often avoids them.
The new technology involves placing a small piece of genetic code in a nanoparticle and giving it a slightly negative charge so it is drawn to dendritic immune cells in the spleen, lymph nodes and bone marrow.
Once there it orders the creation of a cancer molecule – known as an antigen – which is then used as a biological mugshot so that immune cells know what to look out for.
The authors proved that it triggers a strong T-cell response and starts fighting tumours.